絞り込み

16514

広告

Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility.

著者 Takahashi N , Take Y
J Pharmacol Exp Ther.2017 Nov 27 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (400view , 0users)

Full Text Sources

Tegoprazan, (S)-4-((5,7-difluorochroman-4-yl)oxy)-N,N,2-trimethyl-1H-benzo[d]imidazole-6-carboxamide, a potassium-competitive acid blocker (P-CAB), is a novel potent and highly selective inhibitor of gastric H+/K+-ATPase. Tegoprazan inhibited porcine, canine, and human H+/K+-ATPases in vitro with IC50 values ranging 0.29 ~ 0.52 μM while that for canine kidney Na+/K+-ATPase was more than 100 μM. A kinetic analysis revealed that tegoprazan inhibited H+/K+-ATPase with potassium-competitive manner and the binding was reversible. Oral single administrations of tegoprazan ranging 0.3 ~ 30 mg/kg in dogs were well absorbed into blood stream and distributed in gastric tissue/fluid higher than in plasma. Tegoprazan potently inhibited histamine-induced gastric acid secretion in dogs and a complete inhibition was observed at 1.0 mg/kg starting from 1 hr after administration. Moreover, an oral administration of tegoprazan at 1 and 3 mg/kg reversed the pentagastrin-induced acidified gastric pH to the neutral range. Interestingly, 3 mg/kg tegoprazan immediately evoked a gastric phase III contraction of migrating motor complex (MMC) in pentagastrin-treated dogs and similar effects was observed with the other P-CAB, vonoprazan.  Tegoprazan is the novel P-CAB which may provide a new option for the therapy of gastric acid-related and motility-impaired diseases.
PMID: 29180359 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード